Related Experiment Videos
Basic and translational research in neonatal pharmacology.
R M Ward1, R H Lane, K H Albertine
1Pediatric Pharmacology Program, University of Utah Department of Pediatrics, Salt Lake City, 84108, USA. robert.ward@hsc.utah.edu
Summary
Further pharmacologic studies in extremely immature newborns are crucial for optimizing drug therapy and minimizing toxicity. This includes investigating established and novel treatments, utilizing translational models, and fostering physician-scientist training.
Area of Science:
- Neonatal Pharmacology
- Translational Medicine
- Clinical Research
Background:
- Immature newborns surviving today require specialized pharmacologic study.
- Current understanding of drug efficacy and toxicity in this population is limited.
- Existing translational models for neonatal diseases are insufficient.
Purpose of the Study:
- To highlight the need for rigorous pharmacologic studies in extremely immature newborns.
- To emphasize the importance of investigating both established and novel drug therapies.
- To advocate for improved translational models and physician-scientist training.
Main Methods:
- Review of current knowledge gaps in neonatal drug therapy.
- Proposal for the development and utilization of in vivo translational models.
- Analysis of factors impacting the clinician-scientist pipeline.
Main Results:
- Controlled studies are essential to identify beneficial and harmful drug effects and toxicity mechanisms.
- Translational models can identify novel treatments and elucidate mechanisms of existing therapies.
- A decline in clinician-scientists necessitates enhanced training and collaborative environments.
Conclusions:
- Optimizing drug dosing and patient selection can minimize toxicity and maximize efficacy.
- A bidirectional research approach (bedside-to-bench-to-bedside) is vital.
- Strengthening the physician-scientist workforce is critical for advancing neonatal pharmacology.